The purpose of this 2 month phase 2b study is to investigate the dose response of 3 doses of JNJ-42847922 (5,10 and 20 mg) compared to placebo and zolpidem on sleep onset and maintenance and to further document safety and tolerability of JNJ-42847922 upon multiple (14 days) dose administration in participants with insomnia disorder.